Category Archives: Cf

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story stocks' without revenue, let alone profit. But as Warren Buffett has mused, 'If you've been playing poker for half an hour and you still don't know who the patsy is, you're the patsy.' When they buy such story stocks, investors are all too often the patsy.

In the age of tech-stock blue-sky investing, my choice may seem old fashioned; I still prefer profitable companies like CF Energy (CVE:CFY). While that doesn't make the shares worth buying at any price, you can't deny that successful capitalism requires profit, eventually. Conversely, a loss-making company is yet to prove itself with profit, and eventually the sweet milk of external capital may run sour.

View our latest analysis for CF Energy

If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS). That makes EPS growth an attractive quality for any company. CF Energy managed to grow EPS by 7.3% per year, over three years. While that sort of growth rate isn't amazing, it does show the business is growing.

Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. While we note CF Energy's EBIT margins were flat over the last year, revenue grew by a solid 6.8% to CN394m. That's a real positive.

You can take a look at the company's revenue and earnings growth trend, in the chart below. To see the actual numbers, click on the chart.

Since CF Energy is no giant, with a market capitalization of CA$30m, so you should definitely check its cash and debt before getting too excited about its prospects.

Like standing at the lookout, surveying the horizon at sunrise, insider buying, for some investors, sparks joy. That's because insider buying often indicates that those closest to the company have confidence that the share price will perform well. Of course, we can never be sure what insiders are thinking, we can only judge their actions.

We haven't seen any insiders selling CF Energy shares, in the last year. With that in mind, it's heartening that Yongbiao Ding, the Independent Director of the company, paid CN30k for shares at around CN0.44 each.

On top of the insider buying, we can also see that CF Energy insiders own a large chunk of the company. In fact, they own 55% of the company, so they will share in the same delights and challenges experienced by the ordinary shareholders. This makes me think they will be incentivised to plan for the long term - something I like to see. Of course, CF Energy is a very small company, with a market cap of only CA$30m. That means insiders only have CN16m worth of shares, despite the large proportional holding. That's not a huge stake in absolute terms, but it should help keep insiders aligned with other shareholders.

One positive for CF Energy is that it is growing EPS. That's nice to see. Better yet, insiders are significant shareholders, and have been buying more shares. To me, that all makes it well worth a spot on your watchlist, as well as continuing research. Even so, be aware that CF Energy is showing 3 warning signs in our investment analysis , and 2 of those are significant...

As a growth investor I do like to see insider buying. But CF Energy isn't the only one. You can see a a free list of them here.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

More here:

Here's Why I Think CF Energy (CVE:CFY) Is An Interesting Stock - Simply Wall St

ALBANY People in the rare disease community know that in order to make any progress finding cures, they have to band together.

So it was that in 1955 a group of concerned parents whose children werent expected to live past 5 years old came together to create the Cystic Fibrosis Foundation. Few people at the time had the genetic disease, which affects the way a persons body makes mucus and limits their ability to breathe over time. Today, 35,000 people in the U.S. are living with it.

Since the 1950s, treatment of the fatal disease has come a long way. Babies born with cystic fibrosis today are expected to live into their mid-40s and beyond in some cases. And a central reason why is the foundation those parents launched.

Working alongside the CF community, we have effectively transformed a genetic disease in a single generation making CF one of the most amazing stories in medicine today, said Kate Townsend, executive director of the foundations Northeastern New York chapter. Nearly every CF-specific drug available today was made possible with our financial support.

The foundations venture philanthropy model is admired around the world, she said.

By providing funding to companies during the early stages of drug discovery and development when the risk of failure is at its highest the organization incentivizes research that companies would be much less likely to undertake, especially for rare diseases that impact a sliver of the population.

But such research is essential for the people impacted by rare diseases.

The cystic fibrosis community saw an especially significant breakthrough in 1989 when scientists supported by the foundation discovered the defective gene responsible for the disease cystic fibrosis transmembrane conductance regulator and its protein product. The discovery paved the way for future treatments and in 1993 the U.S. Food and Drug Administration approved the first drug developed with financing from the foundation made specifically for cystic fibrosis.

More drugs and therapies have been developed since, but the community is particularly excited these days about advances in gene-based therapies, which seek to treat the underlying cause of the disease rather than its symptoms,Townsend said.

In early November, the foundation announced a first-of-its-kind collaboration with Pioneering Medicines, a division of the life sciences venture capital firm Flagship Pioneering, to spur the development of gene-based therapies that could potentially treat the disease. The foundation will invest up to $110 million in the project, with an initial commitment of $20 million, the organization reported on its website.

Such investments are made possible by the on-the-ground work of the foundations 70 chapters.

Our primary function in the local chapter is to connect with local families to support their needs, and to fund-raise through both individual giving and special events, Townsend said.

The Northeastern New York chapter based in Albany routinely hosts events around the region to raise money for the foundation, including walks, runs, climbs and galas. The chapter is offering a $75 Beer Trail Passport that gives buyers a special discount to 25 local restaurants, breweries, wineries and distilleries through Dec. 30. Information about the passport can be found at https://events.cff.org/NENYBeerTrail.

Townsend said the chapter was able to adjust when the coronavirus pandemic made in-person events impractical. The 65-mile challenge in which individual donors raise funds and complete 65 miles of walking, running, biking, hiking or kayaking over the course of six weeks could easily pivot to become a virtual event, she said.

So you know we just got a little more creative, innovative and we still were able to fund-raise, just not gathering large groups of people in person, Townsend said.

The hope with rare disease fundraising is that people beyond just those directly impacted by the disease will be willing to donate, she said.

Advances in gene-based therapies represent an opportunity to end CF as we know it, she said. We are committed to exploring and advancing all science that has real potential to deliver treatments for the underlying cause of CF ...but we know that no pace is fast enough when you or a loved one is waiting for a breakthrough.

Cystic Fibrosis Foundation Northeastern New York Chaptergive.cff.org/northeastern-newyork

Visit link:

The fight to end cystic fibrosis relies on local chapter - Albany Times Union

ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity

ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development

First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022

Company to host conference call and webcast Wednesday, November 17, 2021 at 8:30 am ET

WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced positive topline results from the monotherapy arms of its Phase 2 clinical trial of ELX-02 in Class 1 cystic fibrosis (CF) patients with at least one G542X nonsense allele mutation. ELX-02 was well tolerated and achieved a statistically significant 5.4mmol/L reduction in sweat chloride in patients at the1.5mg/kg/day dose.

The intra-patient dose escalation stage of the trial has successfully identified 1.5 mg/kg/day as the dose for further development. Based on the statistically significant monotherapy results observed at the 1.5mg/kg/day dose, planning for the advancement of ELX-02 into Phase 3 clinical development has started. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02. In addition, ELX-02 has also been granted Orphan Drug Designation for the treatment of CF patients with nonsense mutations by the FDA and orphan medicinal product designation by the European Medicines Agency.

We are highly encouraged with the topline results from the monotherapy arms of our Phase 2 trial, and believe that ELX-02, if approved, has potential to transform the lives of Class 1 CF patients with nonsense mutations, who do not have any available therapies, said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.

Story continues

Topline Results of ELX-02 Phase 2 Monotherapy Trial in Class 1 Nonsense CF Patients

The Phase 2 clinical trial of ELX-02 was designed to evaluate safety and assess biological activity in G542X nonsense mutation Class 1 CF patients as monotherapy and in combination with ivacaftor. Topline results for the intra-patient dose escalation monotherapy arms are summarized below:

ELX-02 was generally well tolerated in the trial, with no treatment-related serious adverse events noted.

The study met a key secondary endpoint by showing a statistically significant reduction in mean sweat chloride of 5.4 mmol/L (p value=0.0218, n=12 patients) after one week of therapy for ELX-02 dosed at 1.5mg/kg/day.

Short term reductions in sweat chloride have been shown to correlate with biologic activity of the CFTR protein and translate to lung function improvement over the long term.

A potential dose response trend was also seen in mean sweat chloride reduction, with a stronger dose response trend in the subset of patients (post-hoc) that completed the 1.5mg/kg/day dosing.

The reduction in mean sweat chloride in Class 1 CF patients with nonsense mutations who received 1.5mg/kg/day in the trial is similar to the activity in Class 1 CF patient organoids treated with ELX-02 in preclinical experiments.

As expected, no change was observed in forced expiratory volume (FEV1) due to short treatment duration.

While the trial was not designed as a longer-term efficacy study and did not compare ELX-02 to any other agent, results from prior Phase 2 trials with FDA-approved agents for CF can serve as a contextual reference for the level of sweat chloride reduction observed and its potential clinical relevance.

Results of a Phase 2 study with lumacaftor and lumacaftor/ivacaftor combination (Orkambi), an FDA-approved combination CF agent, demonstrated 4.1mmol/L to 5.1 mmol/L reductions in sweat chloride over two- and three-week study durations in Class 2 CF patients with HomF50del mutations.

Results of a phase 2 study with tezacoftor/ivacaftor combination (Symdeko), an FDA-approved combination CF agent, demonstrated a 1.8mmol/L to 5.2 mmol/L reduction in sweat chloride over 28 days in Class 2 CF patients with HomF50del mutations.

Treatment with both these agents resulted in improved lung function as measured by forced expiratory volume FEV1 with longer treatment duration in subsequent Phase 3 trials with Orkambi and Symdeko.

These significant results for sweat chloride, a surrogate for CFTR protein function in patients, are very exciting. I look forward to working with Eloxx on future development of ELX-02, said Prof. Eitan Kerem, Head of The Division of Pediatrics Hadassah Medical Center.

Planned Next Steps for ELX-02 CF Program

ELX-02 in combination with other CF therapies.

First patient dosing has occurred in the expansion arm of the Phase 2 trial, which includes a combination of ELX-02 and Kalydeco (ivacaftor), a CFTR protein potentiator. In preclinical studies, Class 1 CF patient organoids had a 2- to 3-fold higher swelling response with a combination of ELX-02 and Kalydeco than with ELX-02 as a monotherapy. Topline results are expected by the end of the first half of 2022.

With dosing of the first patient, we have now advanced ELX-02 into the Phase 2 combination study and have begun preparations for Phase 3 clinical development, said Vijay Modur MD, PhD, Head of Research & Development of Eloxx.

Inhaled delivery of ELX-02

Eloxx has also begun evaluation of inhaled (nebulizer-based) delivery of the current subcutaneous formulation of ELX-02. Eloxx believes that inhaled delivery has the potential to further improve the activity of ELX-02 as a single agent and in combination with other drugs given potential for increased drug exposure in the lung versus plasma. Prior animal studies have shown a 19-fold increase in ELX-02 exposure at a similar dose when administered as an inhalation agent versus subcutaneously. We expect to submit an Investigational New Drug application the second half of 2022.

About Class 1 CF

CF patients with a Class 1 nonsense mutation remain highly underserved with no approved disease modifying therapies. An estimated 10-12% of CF patients are Class 1 patients with one or both alleles harboring nonsense mutations, leading to less than full length CFTR proteins on the cell membrane in these patients.

Conference Call and Webcast

Eloxxs management will host a conference call and webcast today at 8:30 a.m. ET. A live webcast of the conference call can be accessed through the Investors tab on the Eloxx website, and a replay will be available online after the call. For those planning to ask a question, the dial-in number for the conference call is (866) 913-8546 for domestic participants and (210) 874-7715 for international participants, with Conference ID # 2393967. Please dial in at least 15 minutes in advance to ensure a timely connection to the call.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZM chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxxs lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in clinical development, focusing on cystic fibrosis (US Trial NCT04135495, EU/IL Trial NCT04126473). Eloxx also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.

For more information, please visit http://www.eloxxpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding our expected cash burn and future financial results, the expected timing of trials and results from clinical studies of our product candidates and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words aim, may, will, would, should, expect, explore, plan, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, potential, seeks, or continue or the negative of these terms similar expressions, although not all forward-looking statements contain these words.

Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SECs website at http://www.sec.gov and the Financials & Filings page of our website at https://investors.eloxxpharma.com/financial-information/sec-filings.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact

InvestorsJohn Woolfordjohn.woolford@westwicke.com443.213.0506

MediaLaureen Cassidylaureen@outcomescg.com

SOURCE: Eloxx Pharmaceuticals, Inc.

Read more from the original source:

Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients -...

OTTAWA -- An Ottawa 23-year old with cystic fibrosis says shes in need of a life-saving medication which costs $300,000 dollars a year, but says her private insurance wont pay for it.

I have been basically told that this is my last option, Sara Aldrich says.

Aldrich was diagnosed with cystic fibrosis at an early age, and has lived a mostly active life.

Both my brother and I played competitive soccer, I played for eleven years, she says, we were always out and doing something - some kind of sport.

But she says over the past three years, that changed. Her condition, which affects the lungs, got worse - making everyday tasks difficult.

When I was healthy, I never even thought about how easy it was to do, but now , walking up the stairs I usually cough, I usually end up throwing up. So my life has kind of completely altered since my lung function has gone down.

Aldrich says a new treatment, called Trifakta would change her life.

My lung function is the lowest its ever been, and I cant see it ever going back up unless I get Trikafta.

The drug is approved for use in Canada, but not covered by her private insurance.

The price would need to be reduced by at least 80 to 90 percent for them to be able to pay for it; and, they said that the price of the drug is currently outweighing the benefits of it.

Kim Steele, director of government and community relations with Cystic Fibrosis Canada, says Aldrich is not the only one to be denied,

Were in this weirdly unique situation, in which Canadas public-payers, so our governments, have moved to cover this drug more quickly, than most private insurers, and that just doesnt happen in Canada, she says.

Not everybody can get public insurance; if you have private insurance, depending on where you live in Canada, your government wants to bill them first; and, if your private insurer is not covering it, its a whole bunch of work to try and get it through the public system.

Steele adds that Trikafta treats 98 per cent of the cystic fibrosis community,

Its the single biggest transformation in the history of cystic fibrosis. Its a therapy that is not only slowing the progression of the disease in people, but it is helping people get off the lung transplant list and get on with life.

Aldrich is applying for an OHIP program aimed at young people to hopefully pay for the drug. But her goal is to raise awareness about her situation and help others.

Continuing to fight for everyone else that has CF, and needs this drug - I dont want to stop here.

See the original post here:

'This is my last option:' Ottawa woman with cystic fibrosis says insurance won't cover life-saving medication - CTV Edmonton

Lynn Marr-Moore of Kelly broke down in tears eight years ago when she found out her granddaughter Charlotte Charlie Hugunin would be born with cystic fibrosis.

The tears gave way to a determination to find a cure for the life-threatening illness that affects the respiratory and digestive systems.

I cried for two weeks because we knew Charlie was going to be born with CF, but its remarkable now how much more hope we have than we did eight years ago, Marr-Moore said. We went from feeling so hopeless to feeling so hopeful.

Eight years ago, Marr-Moore formed a nonprofit called Charlies Angels. It startedwith a fundraising bicycle ride, a suggestion of Charlies father Tim, a Nevada High School graduate. The family, including mother Jenny and older sister Alex, lives in Norwalk.

The nonprofit hasgrown to include about a half-dozen events a year, including the Breathing Life Into the Future gala, which will be held Saturday, Nov. 20, at the Hotel Pattee in Perry.

As long as we are going to raise money for research, we are going to have a good time doing it, Marr-Moore said. Charlie is my everyday loving reminder of what I am supposed to be doing with my life.

More Ames news: $200,000 in Arts Capital Grants available, applications due Dec. 3

To date, Charlies Angels has raised about $165,000 and has been recognized by the Cystic Fibrosis Foundation.

For a group our size, we raised the most money of all the groups in the United States, Marr-Moore said. We were honored, but were really just here to get this child well, along with the other children with CF.

Cystic fibrosis is considered an orphan disease. Worldwide, there are only about 300,000 patients. Children had a life expectancy of just 3 or 4 years in the beginning. Now we actually have patients who are 74 because the research has come so far.

All of the money raised by Charlies Angels goes to fund research. It is 100% volunteer work.

When we raise money for cystic fibrosis through Charlies Angels, our money actually stays in the state of Iowa, Marr-Moore said. There are 10 research centers nationwide. Our research center is located at the University of Iowa. Its not part of the university, but they have the lab facilities.

Its the only research center in the United States that's working on the cure. And we have been invited over there several times to meet with the researchers.

The Breathing Life Into the Future gala starts at 5:30 p.m. with check-in and a cash bar. Dinner is at 6 p.m. The evening will includeguest speaker Jim Scholten, a live auction, and a performance by the dueling pianos of Mike and Andy from 8-10 p.m.

More: Whimsical Wine Trailer owner recognized in '40 Women to Watch' list, continues to grow biz

Charlie has won the heart of Iowa State football coach Matt Campbell, Marr-Moore said. She said it began when she was in his office one day hoping to talk to him.

I told him I have a sick granddaughter, and he was so receiving, Marr-Moore said. He said, Tell me about Charlie. So I did, and when I was done he asked how he could help.

Thats how the event Lunch with the Coach started. It is an annual opportunity for Cyclone fans to attend a luncheon and hear from Campbell.

I think Charlie was 3 years old the year coach Campbell invited her to spring practice, Marr-Moore said. She was wearing her Iowa State shirt and a tutu and her cowboy boots. After practice, Matt walked over to us and picked up Charlie.

She told coach Campbell, You know, my dad likes those Hawkeyes. And Matt just smiled and said, Well fix that.

More: Sitting more is linked with worse mental health, Iowa State study says. Light exercise can help

It's Charlie's job tointroduceCampbell at the lunch. The last time, she stood on a chair so she could reach the microphone.

Charlie said, Matt Campbell is my best friend. Hes helping me so Im not sick. And hes really cute, and the place just exploded, Marr-Moore said.

Events to watch for in 2022 include Noodles and Doodles, a pasta dinner by gourmet chef Tim Winter; apainting class with Slater artistShawn Palek; the annual bike ride in the summer; a fashion show starring Charlie; and a continual can drive, where people can donate their empties anytime.

Excerpt from:

Iowa grandmother starts charity devoted to curing cystic fibrosis, gets attention of Iowa State's Matt Campbell - Ames Tribune

Breadcrumb Trail Links

This may be an impossible problem to solve, but it's an easy one to diagnose

Author of the article:

Publishing date:

My colleague David Pugliese reported in the Ottawa Citizen this week that the seemingly never-ending effort to replace our fighter jet fleet has run into yet another delay, marking just the latest low point in our appalling efforts to procure military equipment, of which much is needed. The government was supposed to have selected finalists among the would-be providers of our next generation jet this month, with the selection of a final winner scheduled for early next year. The government no longer says it is committed to that timeline. Its hard to imagine that that means anything else than yet more delays, which is typical of a pattern of deliveries not matching announcements flashy press releases have promised more Rangers with modern weapons, reconnaissance drones, Arctic patrol ships for the Navy, and eventually, new fighter planes to replace the aging CF-18s. Its a long-running problem.

This advertisement has not loaded yet, but your article continues below.

How long running, you might ask? Well, long running enough that in the paragraph above, everything from flashy to aging CF-18s was plucked verbatim out of a column from 2009, written by yours truly in this very same newspaper.

As is the way of things, those aging jets have kept right on aging. There has been some progress. During these last 12 years, we were able to get new bolt action rifles for the Rangers, and one of the Arctic patrol ships is now in service. That concludes the good news.

The only thing that has really changed during that time is that now we have Liberals in power instead of Conservatives, and our elderly CF-18s are even more elderly. If anything, the geopolitical situation around the world has only gotten worse as our jets have gotten older. Canada now routinely sends jets to Europe to assist eastern European NATO allies patrol their skies. A Canadian warship recently joined other allied vessels in a show of strength near Taiwan, which is in Beijings crosshairs. Our alliance with the United States, long our guarantor of protection from external threat, has been through incredible strains these last few years. We simply cannot take for granted that they would defend us in a way that generations of Canadian policymakers had comfortably, if perhaps wrongly, assumed.

This advertisement has not loaded yet, but your article continues below.

This may be an impossible problem to solve, but its an easy one to diagnose: both Stephen Harper and Justin Trudeau have publicly recognized the necessity of replacing the CF-18s; both of them have privately clearly paled at the tens of billions of dollars it will cost to do so. This has been an urgent priority for 20 years. There is simply no incentive for someone to step up, take the reins and fix this problem. And theres always something more politically sexy to spend the money on.

So our pilots take off every day in planes that are at risk of honest-to-God metal fatigue failure if they have to fly too fast or turn sharply. Flying fast and turning sharply, as the reader may know, is the sort of thing that fighter jets could conceivably need to do in the middle of, you know, a mission or something.

This advertisement has not loaded yet, but your article continues below.

Today its the jets, tomorrow it will be something else. Maybe we will try and fail again to replace our 9mm pistols, which were built when Hitlers panzers roamed France. Maybe our plan to replace our navy surface warships will run into some other program-threatening delay or budget overrun. And God help us all, but were gonna need to get going on a submarine replacement sooner rather than later, and if we do an exceptionally good job at it, perhaps my great grandchildren will one day be writing columns in the Planetary Post noting the ongoing delays in delivery.

Conservatives will blame Trudeau for the latest CF-18 delay, and fairly so. He is the guy in the big chair. Hes the boss. Weve had a few elections of late and Trudeaus party keeps winning them. Theres nothing wrong with saying the buck stops with him, because, frankly, it does. Liberals, of course, for their part will note that the Conservatives also dropped the ball on this file and left Trudeau, way back in 2015, not only with a few dozen ancient fighter jets but also a navy that had rusted out. Those Liberals, right as they are, will shift uncomfortably in their seats when its pointed out that theyve been in office for six years since, and as noted above, not much has gotten better.

This advertisement has not loaded yet, but your article continues below.

And it wont. It just wont. This is not a political problem. Its easy to blame Liberals, or Conservatives, or politicians generally, but at this point that is a cop out. This ones on us. This is a Canadian problem. We are bad at this because we do not value it. If we valued it, the government would at least attempt to meet the demand for better. Canadian government competency is something no one has ever gone bust betting against, but we arent even trying. The man who was until very recently the minister of national defence couldnt even seem to get on top of the militarys HR problems, amid the unfolding backdrop of the sexual misconduct omnishambles at the top of the Forces command structure. But sure, this government will get right on replacing many tens of billions of dollars of equipment.

Anyway, what more can be said? Lets check back in another 12 years. Perhaps by then well be flying new jets. But then again, maybe not.

National Post Twitter.com/MattGurney

This advertisement has not loaded yet, but your article continues below.

This advertisement has not loaded yet, but your article continues below.

Sign up to receive the daily top stories from the National Post, a division of Postmedia Network Inc.

A welcome email is on its way. If you don't see it, please check your junk folder.

The next issue of NP Posted will soon be in your inbox.

We encountered an issue signing you up. Please try again

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notificationsyou will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

View post:

Matt Gurney: Canada's aging fighter jets will keep on aging because Trudeau has no incentive to replace them - National Post

Volunteers such as Yvonne Rooney have rattled buckets for years to help those with cystic fibrosis. Campaigners believe Pharmac can fund a breakthrough treatment. Photo / George Novak, File

OPINION

In the coming weeks, Pharmac will confirm how highly it will rank Trikafta, a life-changing medicine for cystic fibrosis, against the other medicines it wants to fund and whether it will go on to fund it.

For many of the 540+ people with cystic fibrosis in New Zealand, these decisions will be the most important Pharmac has ever made. For them, it will be the difference between living an almost normal life and having hope for the future or struggling with declining health and facing the prospect of premature death.

Cystic fibrosis CF for short - is an inherited genetic condition that makes the body produce thick, sticky mucus that causes serious clinical consequences for the lungs, pancreas, liver, intestines, reproductive system, and other organs.

People with CF endure a life-long, demanding, and time-consuming daily regime of lung clearance and medication, medical check-ups, frequent hospitalisations and, for some, lung transplantation. The daily treatment burden for CF is high up to three to four hours per day - and increases with age and severity of the condition.

Having CF shortens your life significantly. Only half of those with CF reach 31 years of age, compared with 80 years for New Zealanders as a whole.

CF also has a major negative impact on the emotional and mental well-being of those with the condition, their families and whnau, due to the stress and anxiety of living with a serious illness and facing premature death. This burden is compounded for the 50+ families in New Zealand with more than one person with CF.

Current treatments for most Kiwis with CF treat only their symptoms, aiming to slow decline and maintain quality of life. But, for the first time, there is a medicine that treats the underlying cause of CF for around 90 per cent of those with the condition - Vertex's triple combination therapy, Trikafta.

Pharmac and its experts have assessed Trikafta and concluded that it's a paradigm-shifting treatment, providing people with CF with substantial improvements in quality of life and life expectancy, and allowing them to live almost normal lives.

These benefits have been clearly demonstrated by the experience of New Zealanders who have been able to access Trikafta and seen life-changing improvements in their health, well-being, and ability to fully participate in life.

15 Nov, 2021 04:00 PMQuick Read

14 Nov, 2021 06:00 PMQuick Read

14 Nov, 2021 04:00 PMQuick Read

10 Nov, 2021 04:00 PMQuick Read

I've seen the effects first-hand. Our 26-year-old daughter was enrolled in Vertex's Managed Access Programme earlier this year.

Before Trikafta, she was spending hours each day doing treatments, struggling to maintain weight, experiencing frequent bouts of uncontrollable coughing, unable to walk very far without becoming breathless and fatigued, and facing the prospect of a lung transplant.

The benefits were immediate: within a week her cough had almost disappeared, and she had started gaining weight; within four weeks she could walk 5km without fatigue; and three months on she's playing tennis again. And on just three pills a day.

The mental and emotional burden of CF has been lifted from her and our whole family. For the first time in 26 years, we aren't living in fear of what's going to happen next.

Trikafta would also benefit New Zealand's health system. Pharmac's experts concluded Trikafta could reduce lung transplants and current treatment by 80 per cent over time, as well as substantially reduce hospitalisations for lung infections, and the use of antibiotics and other medicines.

Recently, Pharmac's experts gave Trikafta a high priority recommendation.

Following this, Pharmac completed its economic assessment and confirmed that it wants to fund Trikafta.

Pharmac has confirmed what the CF community has known all along there is an overwhelming case for funding Trikafta.

Investing in Trikafta would benefit nearly 400 eligible Kiwis with CF by enabling them to live an almost normal life. It would also deliver substantial benefits to the NZ health system. And what better time to fund a medicine that substantially reduces the burden on hospital respiratory services than in the midst of a Covid-19 pandemic?

Pharmac has made much of how expensive Trikafta is. Cystic Fibrosis NZ acknowledges the difficult decisions Pharmac has to make when deciding which medicines to fund from its limited budget, however price needs to be put into perspective.

Pharmac prides itself on achieving some of the best commercial prices for pharmaceuticals in the world and we know that it will not pay the full retail price for Trikafta.

Vertex has reached agreements to supply Trikafta in 22 other countries and already has an agreement with Pharmac to supply Kalydeco, another CF medicine - clear evidence that they can reach a commercial agreement if they want to.

So, Pharmac and Vertex, please progress your commercial negotiations as quickly as possible to agree a fair and reasonable price for Trikafta and make sure that Kiwis with CF have a future to look forward to.

Retiring in late 2019 after a long career in transport, Christine Perrins began volunteering as the advocacy adviser for Cystic Fibrosis NZ in early 2020. Christine leads Cystic Fibrosis NZ's campaign to have Trikafta funded in New Zealand. She has a daughter with cystic fibrosis.

Excerpt from:

Christine Perrins: Give Kiwis with cystic fibrosis a future to look forward to - New Zealand Herald

Winnipeggers are invited to enjoy a safe and fun-filled holiday mini-putt experience presented by Cadillac Fairview

WINNIPEG, MB, Nov. 15, 2021 /CNW/ -Cadillac Fairview (CF) is continuing with its traditions of spirited and engaging community experiences to deliver holiday cheer to Winnipeggers by transforming a portion of its parking lot into Frozen Fairways, an outdoor activity that mergestwo sports that are popular amongCanadians: golf and hockey. From November 27 to December 1, Winnipeggers are encouraged to safely take part in the five day holiday mini-putt experience that replaces a putter, greens and balls with a hockey stick and puck and artificial ice. Frozen Fairwaysfeatures nine-holes, each with exciting Canadiana twistsincluding beloved activities like hockey and curling, and cultural staples like icing fishing and sugar shacks. Participants can reserve their time slot by pre-booking online. Tickets are $5 each and will go on sale starting on November 17. All proceeds from ticket sales will benefit local charities.

Additionally, Cadillac Fairview and RBC Loyalty & Rewards have come together to offer RBC credit cards exclusive perks, including advance to tickets, waived entry fees and more.

CF Polo Park continues to followManitoba health guidelines withsafety as a top priority for its community of guests and employees by integrating extensive health and safety measures in all of its holiday programming. As an outdoor event, the Frozen Fairways experience has enforced physical distancing measures, pre-screening (at home and onsite), regular and frequent sanitation procedures and minimized contact wherever possible. Additionally, to limit the number of guests visiting the activation and to minimize crowding, the experience is only accessible to guests via online registration. Each reservation includes one round of mini putt at the Frozen Fairways and groups will face off ten minutes apart. All guests are encouraged to wear masks and practice physical distancing on and off the course.

Winnipeggers of all ages are welcome to participate in this shareworthy, festive and limited-time activity bringing family and friends together in a reimagined, safe and enjoyable way.

What:

CF Frozen Fairways

Where:

CF Polo Park Saturday, November 27 to Wednesday, December 1, 2021

Interview Opp:

Interview with Peter Havens, General Manager, CF Polo Park

Onsite Photo Opp:

Winnipeggers celebrate the holiday season at CF Polo Park'smagical Frozen Fairways; imagery of Canadian-inspired Frozen Fairways mini-putt course.

For more information, event hours and to make reservations, visit https://shops.cadillacfairview.com/holiday.

About Cadillac FairviewCadillac Fairview (CF) is a globally focused owner, operator, investor, and developer of best-in-class real estate across retail, office, residential, industrial and mixed-use asset classes. Wholly owned by the Ontario Teachers' Pension Plan, CF manages in excess of $35 billion of assets across the Americas and the United Kingdom, with further expansion planned into Europe and Asia.

Internationally, CF invests in communities with like-minded partners, including Stanhope in the UK, Lincoln Property Company in the U.S., and Multiplan in Brazil. The company's Canadian portfolio comprises 68 landmark properties, including the Toronto-Dominion Centre, CF Toronto Eaton Centre, Tour Deloitte, CF Carrefour Laval, CF Chinook Centre and CF Pacific Centre.

Continually striving to make a positive impact in communities where it operates by promoting social connection, growth, and a sustainable future, CF's Purpose is Transforming Communities for a Vibrant Tomorrow. Learn more at cadillacfairview.com and follow CF on LinkedIn.

SOURCE Cadillac Fairview Corporation Limited

For further information: Chelsea Smyth, North Strategic, [emailprotected], 403-616-4956; Anna Ng, Cadillac Fairview, [emailprotected], 416-598-8246

View post:

CF Polo Park Hosts Frozen Fairways Inviting Shoppers to take in New Outdoor Sports Experience from November 27 to December 1 - Canada NewsWire

Breadcrumb Trail Links

An insurer has turned down Sara Aldrich's bid for coverage for Trikafta, described by an advocate as the single greatest innovation in cystic fibrosis history.

Author of the article:

Publishing date:

Sara Aldrich believes you cant put a price on life.

This advertisement has not loaded yet, but your article continues below.

But others are doing just that, and the value theyve assigned to hers is less than the cost of a recently approved drug, Trikafta, that could greatly improve and lengthen it.

Aldrich, a 23-year-old student and Stittsville resident, has cystic fibrosis, a progressive, degenerative multi-system disease that affects mainly the lungs and digestive system by creating a buildup of thick mucus, causing respiratory ailments and making digestion and the absorption of nutrients difficult.

There is no known cure, and in 2018 half of the deaths in Canada from CF involved people younger than 33.

Diagnosed at 16 months, Aldrich led an active lifestyle throughout her childhood and teens, playing competitive soccer. She fully recovered from a lung collapse when she was in Grade 11, but well recalls the warning a doctor at the hospital once offered, telling her to prepare for her death.

This advertisement has not loaded yet, but your article continues below.

Meanwhile, despite a rigorous daily regimen aimed at slowing further decline, Aldrichs lung function has dropped from between 80 and 90 per cent three years ago to the low 40s today. At this rate, she estimates shell be on the lung-transplant list within two years.

My dream is to run a marathon, she says, but, as of right now, even walking up the stairs, I usually cough so much that I throw up. I dont sleep through the night anymore. Im always exhausted. Im seeing myself decline very, very quickly, and we dont know how to put a stop to it. Ive had infection after infection.

Last June, however, CF patients in Canada were encouraged when Health Canada approved Trikafta, a drug that Kelly Grover, president and CEO of Cystic Fibrosis Canada, described as the single greatest innovation in cystic fibrosis history (with) the power to transform the lives of thousands of Canadians.

This advertisement has not loaded yet, but your article continues below.

While not a cure, Cystic Fibrosis Canadas Kim Steele says, its by far the closest thing yet.

We are seeing people who were on the lung transplant list go off the list and return to work or be able to raise children. In the U.S., theres been a baby boom because people with CF are in a spot where theyre thinking, Im healthy enough to have a child and Im going to be around for a while to care for that child.

Trikafta, she adds, has been transformational.

With an annual list price of about $300,000, though, the drug would otherwise be out of reach of all but the wealthiest, so many welcomed the news in September that Ontario was adding Trikafta to the provincial drug program.

Our government has taken urgent action to ensure all cystic fibrosis patients will have more timely access to the effective and life-changing treatments they need, Minister of Health Christine Elliott said.

This advertisement has not loaded yet, but your article continues below.

Because shes still in school, Aldrich was able to apply for coverage through her mothers Ontario Teachers Insurance Plan, or OTIP, benefits for which are paid through Manulife. But OTIP, and many other groups that administer benefits for employee health plans, employs FACET, an independent team of clinical pharmacists that reviews and approves, or denies, requests for specialty drug therapies.

Two weeks ago, Aldrich received an email from FACET, saying her application was denied. The letter cited a recent recommendation by the Canadian Drug Expert Committee (CDEC) of the Canadian Agency for Drugs and Technologies in Health (CADTH), indicating Trikafta was not cost-effective.

A 90% price reduction would be required for Trikafta to reach acceptable costeffectiveness thresholds, the letter read. As a result, the group benefits plan is unable to provide coverage for Trikafta at this time.

This advertisement has not loaded yet, but your article continues below.

Aldrich is, understandably, devastated.

You cant put a price on someones life, and right now it is a matter of life and death.

Imagine being told that theres this amazing drug thats going to save you and then have it ripped away from you.

Steele, meanwhile, is upset, noting that the recommendation from CADTH is a non-binding one intended for the countrys public payers, such as federal and provincial health plans, which take into consideration such factors as long-term hospitalizations and transplants.

Our governments pay for those, and they have decided this drug is worth funding because it has greater value than relegating people to hospital beds for the rest of their lives and shortening their lives, she says.

This advertisement has not loaded yet, but your article continues below.

So, when a private insurer has not moved to cover this, its a real problem because what theyre saying, essentially, is that the government can fund it and they dont have to, and thats shameful.

Additionally, Steele notes, governments typically dont pay the full list price for a drug, instead joining forces to negotiate a better, private deal.

Our governments were able to negotiate that price down, probably not 90 per cent, but somewhere in the middle. And, if our public payers can do that, the private insurers that charge premiums can. Its a total smokescreen, and people are paying into these private plans and not getting the benefits, not getting the drugs they need.

Steele admits theres no easy fix to what is a multi-layered problem, but points to the model used in Quebec, where mandated private insurance led to a cooperative risk-share model.

This advertisement has not loaded yet, but your article continues below.

She also suggests that private payers should be at the table with public ones when negotiating drug prices. Everybody has a bit to pay here, and, if we all put our money in the same pot, we can get better results and people can get the medicine that they need faster and in a more fulsome way.

Mike Sullivan, CEO of Cubic Health, which administers FACET, says the practice of provinces jointly negotiating private agreements with pharmaceutical companies, without insurance companies at the table, creates a two-tier pricing system for expensive drugs such as Trikafta.

(It) creates a very unbalanced playing field, he said in an email. The benefit plans have limited funding to provide all benefits (not just drug), and, if they have to pay multiples of what the public plans have to pay, they cannot cover the same breadth of medications.

This advertisement has not loaded yet, but your article continues below.

In the meantime, Aldrich weighs her options while her lung function worsens. She could apply to the provinces OHIP+ plan, but would have to forego any other coverage under her mothers benefits plan, while any coverage she might be approved for would end next year, when she turns 25. That would at least fill a gap, during which she hopes insurance companies will realize how important Trikafta is to CF patients.

Theres also the possibility that she and her brother Chris, who also has CF, might be able to get Trikafta through the Ontario Disability Support Program.

Weve been working pretty hard for me to get Trikafta because its pretty much my last hope, she says.

Without Trikafta, I dont really plan for my future because theres this fear that I wont have a future. But, with Trikafta, I see myself accomplishing the goals that Ive always set out for myself. Ive always had a passion to teach, and Ive always wanted a family that is my absolute dream. I know that, with Trikafta, I would be able to start a family and have a house and everything that you dream of as someone without CF. I see the potential in my life and living a long life.

This advertisement has not loaded yet, but your article continues below.

Sign up to receive daily headline news from Ottawa Citizen, a division of Postmedia Network Inc.

A welcome email is on its way. If you don't see it, please check your junk folder.

The next issue of Ottawa Citizen Headline News will soon be in your inbox.

We encountered an issue signing you up. Please try again

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notificationsyou will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Continued here:

23-year-old Stittsville student learns life is worth less than the drug that could save it - Ottawa Citizen

Dublin, Nov. 10, 2021 (GLOBE NEWSWIRE) -- The "Ammonium Nitrate Market Research Report by Application, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Ammonium Nitrate Market size was estimated at USD 17.70 billion in 2020, is expected to reach USD 18.58 billion in 2021, and projected to grow at a CAGR of 5.33% reaching USD 24.17 billion by 2026.

Market Statistics

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage

This research report categorizes the Ammonium Nitrate to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Application, the market was studied across Explosives and Fertilizers.

Based on End-user, the market was studied across Agriculture, Civil and Commercial Explosives, Military Explosives, and Mining and Quarrying.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Competitive Strategic Window

Story continues

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ammonium Nitrate Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Ammonium Nitrate Market, including Austin Powder Holdings Company, CF Industries Holdings, Inc., Enaex S.A, EuroChem Group AG, Incitec Pivot Limited, Neochim PLC, Orica Limited., OSTCHEM Holding AG, San Corporation, and URALCHEM Holding P.L.C.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global Ammonium Nitrate Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Ammonium Nitrate Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Ammonium Nitrate Market?4. What is the competitive strategic window for opportunities in the Global Ammonium Nitrate Market?5. What are the technology trends and regulatory frameworks in the Global Ammonium Nitrate Market?6. What is the market share of the leading vendors in the Global Ammonium Nitrate Market?7. What modes and strategic moves are considered suitable for entering the Global Ammonium Nitrate Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview4.1. Introduction4.2. Cumulative Impact of COVID-19

5. Market Dynamics5.1. Introduction5.2. Drivers5.2.1. Need for nitrogen rich fertilizers to increase the agriculture produce from limited arable land5.2.2. Proliferation in construction and mining sector5.2.3. Robust infrastructure development in developing economies5.3. Restraints5.3.1. Volatile price of nitric acid5.4. Opportunities5.4.1. Emerging expansion and remodeling of older production facilities along with manufacture of new ammonium nitrate plants5.4.2. Demand for explosives in defense sector5.5. Challenges5.5.1. Numerous environmental regulations for storage, transport, and packaging

6. Ammonium Nitrate Market, by Application6.1. Introduction6.2. Explosives6.3. Fertilizers

7. Ammonium Nitrate Market, by End-user7.1. Introduction7.2. Agriculture7.3. Civil and Commercial Explosives7.4. Military Explosives7.5. Mining and Quarrying

8. Americas Ammonium Nitrate Market8.1. Introduction8.2. Argentina8.3. Brazil8.4. Canada8.5. Mexico8.6. United States

9. Asia-Pacific Ammonium Nitrate Market9.1. Introduction9.2. Australia9.3. China9.4. India9.5. Indonesia9.6. Japan9.7. Malaysia9.8. Philippines9.9. Singapore9.10. South Korea9.11. Taiwan9.12. Thailand

10. Europe, Middle East & Africa Ammonium Nitrate Market10.1. Introduction10.2. France10.3. Germany10.4. Italy10.5. Netherlands10.6. Qatar10.7. Russia10.8. Saudi Arabia10.9. South Africa10.10. Spain10.11. United Arab Emirates10.12. United Kingdom

11. Competitive Landscape11.1. FPNV Positioning Matrix11.1.1. Quadrants11.1.2. Business Strategy11.1.3. Product Satisfaction11.2. Market Ranking Analysis11.3. Market Share Analysis, by Key Player11.4. Competitive Scenario11.4.1. Merger & Acquisition11.4.2. Agreement, Collaboration, & Partnership11.4.3. New Product Launch & Enhancement11.4.4. Investment & Funding11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles12.1. Austin Powder Holdings Company12.2. CF Industries Holdings, Inc.12.3. Enaex S.A12.4. EuroChem Group AG12.5. Incitec Pivot Limited12.6. Neochim PLC12.7. Orica Limited.12.8. OSTCHEM Holding AG12.9. San Corporation12.10. URALCHEM Holding P.L.C.

13. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/jdfmwk

More:

Insights on the Ammonium Nitrate Global Market to 2026 - Featuring CF Industries, Enaex and Neochim Among Others - Yahoo Finance